Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis

Guo, Guangying; Huang, Aoran; Huang, Xin; Xu, Tianhua; Li, Yao

doi:10.1155/2021/8881393

Cited by 3 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 21 ] reported an almost 4-fold increase in all-cause mortality risk in 423 HD patients in the high compared with the low sST2 tertile, which was independent of galectin-3 and NT-proBNP. Similar associations of sST2 and mortality risk have also been reported in smaller HD cohorts [ 13 ].…”

Section: Discussionsupporting

confidence: 82%

“…SST2 is not attached to the cell membrane and avidly binds IL-33 and thereby functions as a decoy receptor by disrupting IL-33/ST2L signalling. Over the last decade, circulating levels of sST2 have emerged as a powerful prognostic biomarker, particularly in patients with acute and chronic heart failure [ 6 , 7 ], but also in ischaemic heart disease [ 8 , 9 ] and MI [ 10 , 11 ], pulmonary hypertension [ 12 ] and chronic kidney disease (CKD) [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus

Hammer

Genser

Dieplinger

et al. 2022

Clinical Kidney Journal

View full text Add to dashboard Cite

Background Soluble suppression of tumorigenesis 2 (sST2) is a strong prognostic biomarker of cardiovascular (CV) disease. End-stage kidney disease patients are at high risk of CV events and infections. We here investigated the utility of sST2 to predict all-cause and cause-specific mortality in hemodialysis patients with diabetes mellitus. Methods sST2 concentrations were measured in plasma samples of 1196 participants of the German Diabetes and Dialysis (4D) study who had type 2 diabetes mellitus and received maintenance hemodialysis for end stage kidney disease. Hazard ratios (HR) for pre-specified, adjudicated endpoints were determined according to sST2 levels at baseline by multivariate Cox proportional hazards analysis. Results Participants (mean age: 66 years, 54% male) had a median sST2 concentration of 25 ng/ml and were followed-up for 4 years. After adjustment for possible confounders, participants with sST2 concentrations in the highest (>32.6 ng/ml) compared to the lowest (<20.1 ng/ml) quartile exhibited a two-fold higher all-cause mortality risk (HR, 2.06; 95% confidence interval (CI), 1.61-2.61; p<0.001). High sST concentrations (4th vs 1st quartile) were strongly associated with the risk of cardiac death (HR, 2.29; 95% CI, 1.55-3.39; p<0.001). Analysis of individual components of cardiac causes of death showed an increased risk of sudden death (HR, 2.24; 95% CI, 1.33-3.77; p<0.001), death due to myocardial infarction (HR, 2.12; 95% CI, 0.9-5.0; p = 0.087) and heart failure (HR, 3.34; 95% CI, 1.15-9.75; p = 0.027) in participants with sST2 levels in the highest compared to the lowest quartile. Likewise, participants with highest sST2 levels had an increased risk of fatal stroke (HR, 1.92; 95% CI, 1.17-3.14; p = 0.009) and fatal infections (HR, 2.01; 95% CI, 1.2-3.37; p = 0.008). In contrast to fatal CV events, sST2 was not associated with the risk of non-fatal myocardial infarction (HR, 0.68; 95% CI,0.41-1.12; p = 0.132) or non-fatal stroke (HR, 1.28; 95% CI, 0.64-2.53; p = 0.485). Conclusions In hemodialysis patients with diabetes mellitus, high concentrations of sST2 were strongly and independently associated with an increased risk of all-cause mortality, CV mortality, and death due to infection but not non-fatal CV events.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Introductionmentioning

confidence: 99%

Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus

Hammer

Genser

Dieplinger

et al. 2022

Clinical Kidney Journal

View full text Add to dashboard Cite

show abstract

Association of soluble suppression of tumorigenicity 2 with mortality and adverse outcomes in chronic kidney disease: a systematic review and meta-analysis

Bellos,

Marinaki,

Lagiou

et al. 2024

Clin Exp Nephrol

View full text Add to dashboard Cite

Background Early risk stratification is necessary to prevent chronic kidney disease progression and complications. This systematic review aims to evaluate the association of soluble suppression of tumorigenicity 2 (sST2), a member of the interleukin-1 receptor family, with all-cause mortality, cardiovascular disease and renal function deterioration among chronic kidney disease patients. Methods PubMed, Scopus, Web of Science, CENTRAL and Google Scholar were systematically searched from inception to December 20, 2023. Cohort studies examining the prognostic role of sST2 levels in pre-dialysis and dialysis patients were included. In case of 3 or more studies per outcome, conventional and dose–response meta-analyses were conducted. Results Overall, 21 studies were included comprising 15,100 patients. In pre-dialysis patients, the qualitative synthesis of studies suggested that high sST2 is associated with significantly increased all-cause mortality, while evidence regarding cardiovascular events or kidney disease progression was conflicting. In the dialysis population, high sST2 was linked to an elevated risk of all-cause (Hazard ratio-HR: 3.00, 95% confidence intervals-CI: 1.95–4.61) and cardiovascular (HR: 2.38, 95% CI: 1.69–3.34) mortality. Dose–response meta-analysis suggested a log-linear association of sST2 with both all-cause (χ2: 34.65, p value < 0.001) and cardiovascular (χ2: 29.14, p value < 0.001) mortality, whereas findings regarding cardiovascular events were limited with mixed results. Conclusions High sST2 values are associated with an increased risk of all-cause mortality in pre-dialysis and dialysis patients, as well as with an elevated risk of cardiovascular mortality in the dialysis population. Further studies are needed to elucidate its potential association with cardiovascular events and kidney disease progression.

show abstract

Osteoprotegerin and Inflammation in Incident Peritoneal Dialysis Patients

Małecki,

Okulewicz,

Lisak

et al. 2024

JCM

View full text Add to dashboard Cite

Objectives: Osteoprotegerin (OPG) is a member of the tumor necrosis factor receptor family involved in processes in many inflammatory states. OPG concentration is enhanced in the majority of chronic kidney disease (CKD) patients and those undergoing renal replacement therapy. The aim of the study was to assess the relation of OPG and chronic inflammation in peritoneal dialysis (PD) patients and to evaluate whether OPG concentrations in plasma and dialysate were related to plasma and dialysate levels of proinflammatory mediators (interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP), interleukin 33 (IL-33) and interleukin 1 receptor-like 1IL-1RL1 (IL-1RL1, sST2)). Methods: The study included 37 patients of the Peritoneal Dialysis Center, Department of Nephrology, Transplantology and Internal Medicine, Szczecin, Poland, 4–6 weeks after the onset of peritoneal dialysis therapy. During a peritoneal equilibration test, plasma (at 2 h) and dialysate (at 4 h) OPG, IL-33, 1IL-1RL1 (sST2), IL-6 and hsCRP concentrations were determined. Results: Plasma concentration of OPG did not correlate with dialysate OPG level (Rs = 0.04, p = 0.8). There was a strong positive correlation between plasma OPG concentrations and plasma IL-1RL1 (sST2) (Rs = 0.41; p = 0.01), plasma IL-6 (Rs = 0.38; p = 0.01) and plasma hsCRP (Rs = 0.35; p = 0.02). Dialysate OPG concentrations were positively associated with dialysate IL-1RL1 (sST2) (Rs = 0.37; p = 0.02) and dialysate IL-6 levels (Rs = 0.44; p = 0.005). Multivariate analysis showed that higher IL-1RL1 (sST2) (ß = +0.38, p = 0.006), higher plasma hsCRP (ß = +0.32, p = 0.02) and older age (ß = +0.35, p = 0.01) were independent determinants of higher plasma OPG concentration and that higher concentrations of dialysate IL-6 (ß = +0.37, p = 0.02) were independent determinants of higher dialysate OPG concentration. Conclusions: Both plasma and dialysate OPG levels are associated with the severity of systemic and local inflammation illustrated by the plasma and dialysate concentrations of IL-1RL1 (sST2), hsCRP and IL-6, suggesting that OPG might have a pivotal role in explaining the milieu of systemic and intraperitoneal inflammation.

show abstract

Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis

Cited by 3 publications

References 33 publications

Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus

Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus

Association of soluble suppression of tumorigenicity 2 with mortality and adverse outcomes in chronic kidney disease: a systematic review and meta-analysis

Osteoprotegerin and Inflammation in Incident Peritoneal Dialysis Patients

Contact Info

Product

Resources

About